An observational study in Schwannoma, Vestibular, sponsored by Hartmann Oncology Radiotherapy Group, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Hartmann Oncology Radiotherapy Group, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Neuroma, Acoustic with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Neuroma, Acoustic · France.
Among the 15 studies in Neuroma, Acoustic with a site in France, this one is the only one that started in 2016, is one of 7 observational ones, and was the 15th registered.
100 studies on the registry are indexed under Neuroma, Acoustic; 28 are open to participants now.
Browse Neuroma, Acoustic studies →3 of the 15 studies in Neuroma, Acoustic with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18–65
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–90 · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 22 Neuroma, Acoustic studies recruiting now, 9 (41%) set no upper age limit and 8 (36%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 61 across 26 observational studies indexed under Neuroma, Acoustic.
Median enrollment 23 across the 8 interventional studies, 51 across the 7 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 15 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hartmann Oncology Radiotherapy Group, France as lead sponsor.
Hartmann Oncology Radiotherapy Group, France has 1 study filed under Neuroma, Acoustic — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuroma, Acoustic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660082Hospices Civils de LyonEarly Rehabilitation Using Head Impulse Test for Acute Vestibular Deficit | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Neuroma, Acoustic with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Historically, the management of schwannomas has relied primarily on observation, surgery, or conventional radiotherapy techniques. However, while surgery is curative, it carries significant risks-including postoperative complications, neurological deficits, and substantial morbidity-particularly for intracranial schwannomas located near critical neurovascular structures.
Stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT) has emerged as a less invasive alternative, offering remarkable precision in targeting tumor tissue while sparing adjacent healthy structures. This technique employs high doses of radiation focused precisely on the tumor, thereby controlling tumor growth with minimal morbidity. Several studies have demonstrated that SRS is particularly effective for small- to medium-sized schwannomas, yielding high tumor control rates (exceeding 90% at 5 years) while preserving neurological function. Despite this, the natural history, clinical data, and post-treatment outcomes associated with schwannomas remain incompletely understood or not fully elucidated in scientific literature.
Schwannomas are benign tumors arising from Schwann cells in the peripheral nervous system; the most common type is the vestibular schwannoma (also known as an acoustic neuroma). Although these tumors are non-malignant, their location-particularly on cranial or spinal nerves-can lead to serious complications such as hearing loss, balance disorders, and neurological dysfunction. Treatment aims to prevent tumor growth and preserve neurological function.
The natural history, clinical data, and post-treatment outcomes of schwannomas remain incomplete or not fully elucidated.
Stereotactic radiosurgery (SRS) has emerged as a less invasive alternative, offering remarkable precision in targeting tumor tissue while sparing adjacent healthy structures. This technique employs high doses of radiation focused precisely on the tumor, thereby controlling tumor growth with minimal morbidity. Several studies have demonstrated that SRS is particularly effective for small- to medium-sized schwannomas, yielding high tumor control rates (exceeding 90% at 5 years) while preserving neurological function. Despite this, the natural history, clinical data, and post-treatment outcomes associated with schwannomas remain incompletely understood or not fully elucidated in scientific literature.
Real-world data enables a better understanding of diseases, the optimization of care pathways, and the acceleration of the development of new treatments or personalized diagnostics.
Patients managed for a schwannoma at the Hartmann Radiotherapy Institute and treated with stereotactic radiotherapy .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with vestibular schwannoma
Efficacy data on stereotactic radiotherapy for the treatment of schwannomas
MRI data (comparison of initial schwannoma volume with follow-up volume)
Time frame: 6 months
Side effects associated with stereotactic radiotherapy treatment
Adverse events (measured by CTCAE v5.0 criteria - Common Terminology Criteria for Adverse Events)
Time frame: 6 months
Survival
6-month post-treatment survival rate
Time frame: 6 months
Quality of life assessment
Quality-of-life questionnaires (EORTC-QLQ-C30). Most questions use a 4-point scale from "Not at all" to "Very much" with a one-week recall period. Raw scores are averaged and transformed into a 0-100 scale using official EORTC scoring algorithms.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2016 to primary completion in Aug 2026, 127 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.